L&S Knock-Out 5CV 09.12.2024/ DE000LX34138 /
2024-06-05 8:16:21 AM | Chg.-0.28 | Bid8:55:52 PM | Ask8:55:52 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.48EUR | -10.14% | 2.82 Bid Size: 5,000 |
2.86 Ask Size: 5,000 |
CUREVAC N.V. O.N. | 1.50 EUR | 2024-12-09 | Call |
GlobeNewswire
2022-03-25
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA...
GlobeNewswire
2022-01-13
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration o...
GlobeNewswire
2022-01-11
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply ...
GlobeNewswire
2021-12-17
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatme...
GlobeNewswire
2021-12-07
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutation...
GlobeNewswire
2021-12-02
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV...
GlobeNewswire
2021-11-17
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COV...
GlobeNewswire
2021-11-12
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovim...
GlobeNewswire
2021-07-28
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19...
GlobeNewswire
2021-06-21
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for...
GlobeNewswire
2021-05-27
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from t...